Literature DB >> 12513120

Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Michael J Campbell1, Wendy S Wollish, Margaret Lobo, Laura J Esserman.   

Abstract

Female murine mammary tumor virus (MMTV)/neu transgenic mice, expressing a wild-type rat neu oncogene driven by an MMTV promoter, develop focal mammary adenocarcinomas that are pathologically very similar to human breast tumors. Two new cell lines were established from a mammary tumor that arose in a female MMTV/neu transgenic mouse. One of these lines, mammary carcinoma from Neu transgenic mouse A (MCNeuA), has an epithelial morphology, is cytokeratin positive, and expresses high levels of the neu transgene. Karyotyping and comparative genomic hybridization analyses demonstrated genomic alterations in the MCNeuA cell line. The other line, N202Fb3, has a fibroblast morphology, is cytokeratin negative, and expresses the neu transgene at a very low level. This cell line also expresses smooth muscle alpha-actin, suggesting that it is a myofibroblast line. The MCNeuA cell line is tumorigenic when injected into syngeneic MMTV/neu transgenic mice, with an in vivo doubling time of about 14 d. The rationale for establishing this tumor cell line was to provide a tumor transplantation system for rapidly assessing immunotherapeutic interventions before testing in the more cumbersome model of spontaneous tumor development in the MMTV/neu transgenic mice. Mice immunized with a Neu extracellular domain protein vaccine were protected against a subsequent inoculation of MCNeuA cells, indicating that this cell line will be useful for evaluating cancer vaccine strategies. This tumor cell line may also prove useful in studying the biological properties of the neu oncogene and its role in the malignant process. In addition, the tumor-derived fibroblast line may be useful for studying tumor-stromal cell interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12513120     DOI: 10.1290/1071-2690(2002)038<0326:EAFCLD>2.0.CO;2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  62 in total

1.  Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.

Authors:  S R Ritland; G J Rowse; Y Chang; S J Gendler
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  Smad4 (homolog of human DPC4) and Smad2 (homolog of human JV18-1): candidates for murine lung tumor resistance and suppressor genes.

Authors:  T R Devereux; C H Anna; A C Patel; C M White; M F Festing; M You
Journal:  Carcinogenesis       Date:  1997-09       Impact factor: 4.944

3.  DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.

Authors:  Y Chen; D Hu; D J Eling; J Robbins; T J Kipps
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

4.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

5.  Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes.

Authors:  B Hendrich; C Abbott; H McQueen; D Chambers; S Cross; A Bird
Journal:  Mamm Genome       Date:  1999-09       Impact factor: 2.957

6.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

Authors:  G B Tremblay; A Tremblay; N G Copeland; D J Gilbert; N A Jenkins; F Labrie; V Giguère
Journal:  Mol Endocrinol       Date:  1997-03

7.  Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

Authors:  W Z Wei; W P Shi; A Galy; D Lichlyter; S Hernandez; B Groner; L Heilbrun; R F Jones
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

8.  Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors.

Authors:  C R Herzog; R W Wiseman; M You
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

Review 9.  Transgenic models of tumor development.

Authors:  J M Adams; S Cory
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

10.  Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

Authors:  M J Campbell; L Esserman; N E Byars; A C Allison; R Levy
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

View more
  15 in total

1.  HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Authors:  Maciej Kmieciak; Keith L Knutson; Catherine I Dumur; Masoud H Manjili
Journal:  Eur J Immunol       Date:  2007-03       Impact factor: 5.532

2.  Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.

Authors:  Yvonne Fierz; Ruslan Novosyadlyy; Archana Vijayakumar; Shoshana Yakar; Derek LeRoith
Journal:  Endocr Relat Cancer       Date:  2010-10-05       Impact factor: 5.678

3.  Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: a mathematical model and experiments.

Authors:  Yangjin Kim; Julie Wallace; Fu Li; Michael Ostrowski; Avner Friedman
Journal:  J Math Biol       Date:  2009-11-10       Impact factor: 2.259

4.  Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.

Authors:  Nirmala Parajuli; Wolfgang Doppler
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-16       Impact factor: 2.416

5.  Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

Authors:  Ruslan Novosyadlyy; Danielle E Lann; Archana Vijayakumar; Anne Rowzee; Deborah A Lazzarino; Yvonne Fierz; Joan M Carboni; Marco M Gottardis; Patricia A Pennisi; Alfredo A Molinolo; Naamit Kurshan; Wilson Mejia; Stefania Santopietro; Shoshana Yakar; Teresa L Wood; Derek LeRoith
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

6.  Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4.

Authors:  Y Sun; S Cao; M Yang; S Wu; Z Wang; X Lin; X Song; D J Liao
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

7.  Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.

Authors:  E J Gallagher; Y Fierz; A Vijayakumar; N Haddad; S Yakar; D LeRoith
Journal:  Oncogene       Date:  2011-10-31       Impact factor: 9.867

8.  Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.

Authors:  Cesar F Ortega-Cava; Srikumar M Raja; Zenab Laiq; Tameka A Bailey; Haitao Luan; Bhopal Mohapatra; Stetson H Williams; Aaron C Ericsson; Rasna Goswami; Manjari Dimri; Lei Duan; Vimla Band; Mayumi Naramura; Hamid Band
Journal:  J Carcinog       Date:  2011-11-30

9.  Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.

Authors:  Yvonne Fierz; Ruslan Novosyadlyy; Archana Vijayakumar; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes       Date:  2009-12-03       Impact factor: 9.461

10.  Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer.

Authors:  Jinyang Wang; Yuan Zhang; Yi Xiao; Xiangliang Yuan; Ping Li; Xiao Wang; Yimin Duan; Victoria L Seewaldt; Dihua Yu
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.